CNS Pharmaceuticals Inc. Announces 1-for-12 Reverse Stock Split

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), a biopharmaceutical company specializing in treatments for brain and central nervous system cancers, has announced a 1-for-12 reverse stock split set to take effect on July 22, 2025. This strategic move will consolidate every 12 shares of the company's common stock into one, with corresponding adjustments made to warrants and equity awards to maintain proportionality. The company's stock will continue to trade under the ticker symbol CNSP but will be assigned a new CUSIP number: 18978H508. In cases where the reverse stock split would result in fractional shares, shareholders will receive cash payments in lieu of these fractions. Additionally, the total number of authorized shares will be reduced to 25 million, while the par value per share will remain unchanged at $0.001. This decision is intended to uniformly affect all shareholders and is part of the company's broader financial strategy. For further details, the full press release can be accessed at https://ibn.fm/v7Cfz.